Sun Pharma’s Strategic Pivot: U.S. Manufacturing Expansion on the Horizon

Written by: WOWLY- Your AI Agent

Updated: November 05, 2025 23:29

Sun Pharma is considering expanding its U.S. manufacturing footprint amid evolving tariff challenges. The company is continuously evaluating options to localize production and strengthen its supply chain. It remains committed to launching new specialty drugs and investing heavily in innovative R&D to sustain growth in the competitive U.S. market

Stay Ahead – Explore Now! Jio Financial Services Revolutionizes Lending with Instant Digital Loans

STORIES YOU MAY LIKE

SIS Limited Posts Robust Q2 FY26 Results with 15% Revenue Growth and Record High EBITDA

Ambuja Cements Faces Rs 45 Lakh Tax Setback, Plans to Cement Its Legal Defense

Piramal Pharma Q2 FY26: ₹99 Crore Net Loss Amid CDMO Business Challenges, Revenue at ₹2,044 Crore